Wei-Chien Huang Selected Research

Therapeutics

3/2024	Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2-positive breast cancer.
3/2021	Drug Screening of Potential Multiple Target Inhibitors for Estrogen Receptor-α-positive Breast Cancer.
1/2021	Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progression by suppressing EZH2-mediated epigenetically silencing of p21 in triple-negative breast cancer cells.
1/2021	Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.
1/2017	MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
10/2014	Targeting L1 cell adhesion molecule expression using liposome-encapsulated siRNA suppresses prostate cancer bone metastasis and growth.
9/2013	EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
6/2011	Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
3/2011	HDAC inhibition decreases the expression of EGFR in colorectal cancer cells.
3/2009	Induction of Akt activity by chemotherapy confers acquired resistance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wei-Chien Huang Research Topics

Disease

43	Neoplasms (Cancer) 03/2024 - 10/2004
18	Breast Neoplasms (Breast Cancer) 03/2024 - 08/2007
12	Hepatocellular Carcinoma (Hepatoma) 02/2019 - 01/2012
9	Neoplasm Metastasis (Metastasis) 11/2022 - 04/2013
8	Lung Neoplasms (Lung Cancer) 11/2022 - 01/2011
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2011
6	Inflammation (Inflammations) 06/2023 - 09/2004
6	Infections 06/2023 - 01/2012
6	Triple Negative Breast Neoplasms 01/2021 - 01/2013
6	Carcinogenesis 01/2014 - 09/2004
4	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 09/2013
3	COVID-19 01/2022 - 01/2021
3	Oncogene Addiction 01/2018 - 11/2013
2	Experimental Arthritis 01/2022 - 01/2022
2	Rheumatoid Arthritis 01/2022 - 01/2022
2	Chronic Hepatitis B 01/2014 - 01/2012
1	Burns 01/2023
1	Macular Degeneration (Age-Related Maculopathy) 01/2023
1	Chondrosarcoma 01/2023
1	Lactic Acidosis 01/2022
1	Osteoarthritis 01/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Heart Arrest (Cardiac Arrest) 01/2021
1	Shock 01/2021
1	Coronavirus Infections 01/2021

Drug/Important Bio-Agent (IBA)

15	Tyrosine Kinase InhibitorsIBA 03/2024 - 01/2011
15	ErbB Receptors (EGF Receptor)IBA 01/2023 - 05/2008
14	Proteins (Proteins, Gene)FDA Link 06/2023 - 03/2009
11	Lapatinib (GW572016)FDA Link 03/2024 - 04/2013
6	Phosphotransferases (Kinase)IBA 01/2021 - 05/2008
6	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 05/2008
6	NF-kappa B (NF-kB)IBA 11/2013 - 10/2004
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 08/2007
4	SmokeIBA 11/2022 - 11/2017
4	human ERBB2 proteinIBA 10/2021 - 04/2013
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 06/2011
3	MelatoninIBA 01/2023 - 02/2019
3	Small Interfering RNA (siRNA)IBA 02/2019 - 01/2014
3	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2019 - 03/2011
3	hepatitis B virus X proteinIBA 01/2016 - 01/2012
3	Gefitinib (Iressa)FDA Link 09/2013 - 01/2011
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 06/2011 - 05/2008
2	7-hydroxycoumarin (umbelliferone)IBA 03/2024 - 06/2023
2	Serine Proteases (Serine Protease)IBA 03/2024 - 01/2021
2	Serine (L-Serine)FDA Link 01/2023 - 01/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 01/2017
2	Peptides (Polypeptides)IBA 02/2022 - 01/2013
2	CytokinesIBA 01/2022 - 01/2022
2	antcin KIBA 01/2022 - 01/2022
2	Estrogen ReceptorsIBA 03/2021 - 11/2013
2	Proteasome InhibitorsIBA 09/2019 - 11/2013
2	Sodium-Glucose Transporter 1IBA 01/2019 - 05/2008
2	Conditioned Culture MediaIBA 01/2019 - 01/2018
2	Interleukin-6 (Interleukin 6)IBA 09/2016 - 11/2015
2	SERPIN-B5 (maspin)IBA 08/2016 - 09/2015
2	MicroRNAs (MicroRNA)IBA 09/2015 - 05/2013
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2014 - 09/2013
2	Messenger RNA (mRNA)IBA 01/2014 - 01/2014
2	Polysaccharides (Glycans)IBA 01/2014 - 01/2012
2	Tyrosine (L-Tyrosine)FDA Link 09/2013 - 01/2013
2	SodiumIBA 09/2013 - 01/2013
2	SymportersIBA 09/2013 - 01/2013
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 10/2004 - 09/2004
1	Peptide Hydrolases (Proteases)FDA Link 03/2024
1	eriodictyolIBA 03/2024
1	Glutamine (L-Glutamine)FDA Link 01/2023
1	AmphiregulinIBA 01/2023
1	erucylphosphocholineIBA 01/2023
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Alanine (L-Alanine)FDA Link 01/2023
1	AlkaliesIBA 01/2023
1	NADP (NADPH)IBA 01/2023
1	Cisplatin (Platino)FDA LinkGeneric 01/2023
1	LigandsIBA 01/2023
1	Cysteine (L-Cysteine)FDA Link 01/2023
1	GlutaminaseIBA 01/2023
1	IntegrinsIBA 11/2022
1	pyreneIBA 11/2022
1	OsteopontinIBA 11/2022
1	GC376IBA 05/2022
1	Fast GreenIBA 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	Hematoxylin (Haematoxylon)IBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2022
1	SARS-CoV-2 spike proteinIBA 01/2022
1	safranine T (safranin)IBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Protein Kinase CIBA 01/2022
1	Angiotensin-Converting Enzyme 2IBA 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 09/2021
1	HesperidinIBA 08/2021
1	Pemetrexed (MTA)FDA Link 03/2021
1	hamamelitanninIBA 03/2021
1	AminopterinIBA 03/2021
1	camostatIBA 01/2021
1	nafamostatIBA 01/2021

Therapy/Procedure

11	Therapeutics 03/2024 - 05/2008
1	Oral Administration 06/2023
1	Neoadjuvant Therapy 09/2021